Form 4: Rhythm Pharmaceuticals Executive Yann Mazabraud Sells Shares Under 10b5-1 Trading Plan

Yann Mazabraud, EVP, Head of International at Rhythm Pharmaceuticals, sold 6,745 shares of common stock at an average price of $65.0773 under a pre-arranged 10b5-1 trading plan.

Summary

• On April 29, 2025, Yann Mazabraud, EVP, Head of International at Rhythm Pharmaceuticals, sold 6,745 shares of common stock.
• The sale was executed under a Rule 10b5-1 trading plan adopted on December 13, 2024.
• The shares were sold at a weighted average price of $65.0773, with individual transactions ranging from $65.00 to $65.22 per share.
• Following the transaction, Mazabraud directly owns 37,655 shares of Rhythm Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. The use of a 10b5-1 plan suggests the sale was pre-planned and doesn't necessarily reflect a negative outlook on the company.

Industry Context

Sales by company executives are a normal part of corporate governance. The use of a 10b5-1 trading plan suggests the sales were pre-planned and not based on any inside information at the time of the transaction.

Stakeholder Impact

• The sale of shares by an executive could be perceived negatively by some shareholders, although the use of a 10b5-1 plan mitigates this concern.

Key Dates

Keywords

Rhythm Pharmaceuticals, Yann Mazabraud, Form 4, insider trading, stock sale, RYTM, 10b5-1 plan, executive, share sale